NEW YORK (GenomeWeb News) – Epic Sciences today announced it has completed its Series B financing round raising $13 million.
Germany's Curetis has initiated a prospective clinical trial in the European Union for its Unyvero molecular testing system and P50 Pneumonia test cartridge, the company said in February.
By Ben Butkus
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Curetis today announced its Series A financing round has increased by €9.6 million ($13.3 million) bringing the total amount raised in the round to €34.1 million.
According to founder and CEO Scott Tanner, the funds will go primarily toward ramping up production of CyTOF instruments, reagent production, and the establishment of a global sales and service team.
In a commentary at eLife, Brandeis University's Eve Marder calls on researchers to value and pursue truth.
Researchers have developed a way to quickly edit white blood cells, according to the New York Times.
In Science this week: rice gene enables plants to grow quickly in times of flooding, and more.
Education-linked genetic variants could also predict a small portion of a person's social mobility, Newsweek reports.